<DOC>
	<DOCNO>NCT02907229</DOCNO>
	<brief_summary>This trial conduct evaluate safety technical effectiveness use NCVC-CS1 , newly develop honeycomb microporous cover stent , treatment intracranial aneurysm difficult cure conventional surgical endovascular procedure .</brief_summary>
	<brief_title>Safety Efficacy Honeycomb Microporous Covered Stents ( NCVC-CS1 ) Treatment Intracranial Aneurysms</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Intracranial Aneurysm</mesh_term>
	<criteria>( Provisional registration ) 1 . Age 20 75 year . 2 . Target lesion unruptured aneurysm regardless prior treatment diagnose angiography , CTA , MRA within 180 day Target aneurysm locate petrous/cavernous portion internal carotid artery , intradural vertebral artery except union , basilar artery orifice superior cerebellar artery . Target aneurysm consider difficult treat conventional surgical/endovascular procedure Target aneurysm sac diameter exceed 7 mm . Target aneurysm neck diameter 4 mm ratio `` dome/neck '' small 2 . 3 . Modified Rankin score 3 less 4 . Agreement participate study inform consent sign patient . ( definitive registration ) 1 . Target lesion must reconfirm angiography interventional procedure compatible condition follow : Target aneurysm locate petrous/cavernous portion internal carotid artery , intradural vertebral artery except union , basilar artery orifice superior cerebellar artery . Target aneurysm consider difficult treat conventional surgical/endovascular procedure Target aneurysm sac diameter exceed 7 mm . Target aneurysm neck diameter 4 mm ratio `` dome/neck '' small 2 . Parent artery target aneurysm accessible investigational device The diameter parent artery 3.5 5 mm . ( Provisional registration ) 1 . Any invasive surgical procedure within 30 day registration . 2 . Prior stent implantation site target aneurysm 3 . Existence intracranial tumor , arteriovenous malformation intervention consider necessary , coexistence unruptured intracranial aneurysm whose sac diameter 5mm within target vessel . 4 . Coexistence unruptured intracranial aneurysm plan intervention 5 . Target vessel suitable delivery placement cover stent anatomical configuration ( i.e . severe bend tortuosity ) . 6 . More 50 % stenosis target vessel proximity include extracranial region . 7 . Any intracranial hemorrhage within 42 day registration . 8 . Comorbid condition may limit survival less 6 month , difficult observe patient 6 month . 9 . Renal dysfunction whose serum creatinine 2.0 10 . Contraindications antiplatelet anticoagulant treatment allergy hemorrhagic diathesis . 11 . Platelets le 100,000/mm3 know dysfunction platelet . 12 . Active bacterial infection . 13 . Any cardiac , hematological , intracranial , vessel disease consider high risk neurological event ( severe cardiac failure , atrial fibrillation , arteritis , know carotid artery stenosis , etc. ) . 14 . History severe allergy contrast dye . 15 . Known allergy cobaltchromium alloy polyurethane . clopidogrel , heparin , nitinol , local general anesthesia 16 . Subjects enrol , plan participate clinical trial intervention study . 17 . Pregnant woman 18 . Unsuitable patient judge physician attend trial . ( definitive registration ) 1 . History invasive surgical procedure provisional registration . 2 . Any new neurological sign within 24 hour prior procedure .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>